MK2 is a therapeutic target for high-risk multiple myeloma.
Gu C, Cheng H, Yang H, Bian Y, Wang Y, Zhang Y, Pisano M, Hu G, Yang Y.
Gu C, et al. Among authors: zhang y.
Haematologica. 2021 Jun 1;106(6):1774-1777. doi: 10.3324/haematol.2017.182121.
Haematologica. 2021.
PMID: 29567777
Free PMC article.
No abstract available.